Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/chronic-myelomonocytic-leukaemia-diagnosis-and-therapeutic-ZbE4Ix8F3J
References (38)
-
P. Fenaux, G. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List, S. Gore, J. Seymour, J. Bennett, J. Byrd, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, L. Silverman (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.The Lancet. Oncology, 10 3
-
S Molica, P Iannaccuro, A Albeti (1990)
Chronic myelomonocytic leukemia: a test of a proposed staging systemAm J Haematol, 35
-
A. Pich, L. Riera, F. Sismondi, L. Godio, L. Bonino, F. Marmont, P. Celle (2009)
JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemiaJournal of Clinical Pathology, 62
-
A. Storniolo, W. Moloney, D. Rosenthal, C. Cox, J. Bennett (1990)
Chronic myelomonocytic leukemia.Leukemia, 4 11
-
C. Geary, D. Catovsky, E. Wiltshaw, G. Milner, M. Scholes, S. Noorden, L. Wadsworth, S. Muldal, J. Maciver, D. Galton (1975)
Chronic Myelomonocytic LeukaemiaBritish Journal of Haematology, 30
-
A. Kohlmann, V. Grossmann, H. Klein, S. Schindela, T. Weiss, B. Kazak, F. Dicker, S. Schnittger, M. Dugas, W. Kern, C. Haferlach, T. Haferlach (2010)
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 24
-
V. Gelsi-Boyer, V. Trouplin, J. Adélaı̈de, Julien Bonansea, N. Cervera, N. Carbuccia, A. Lagarde, T. Prebet, M. Nezri, D. Sainty, S. Olschwang, L. Xerri, M. Chaffanet, M. Mozziconacci, N. Vey, D. Birnbaum (2009)
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaBritish Journal of Haematology, 145
-
A. Worsley, D. Oscier, J. Stevens, S. Darlow, A. Figes, G. Mufti, T. Hamblin (1988)
Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survivalBritish Journal of Haematology, 68
-
W. Gorczyca (2004)
Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML).Methods in cell biology, 75
-
I. González-Medina, J. Bueno, A. Torrequebrada, Andrés López, T. Vallespí, I. Massagué (2002)
Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center.Leukemia research, 26 9
-
M. Beran, E. Estey, S. O’Brien, F. Giles, C. Koller, S. Kornblau, M. Keating, H. Kantarjian (1998)
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.Leukemia & lymphoma, 31 5-6
-
Yin Xu, R. Mckenna, N. Karandikar, Alex Pildain, S. Kroft (2005)
Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis.American journal of clinical pathology, 124 5
-
(2008)
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes -
A. Jones, S. Kreil, K. Zoi, K. Waghorn, Claire Curtis, Lingyan Zhang, J. Score, R. Seear, A. Chase, F. Grand, H. White, C. Zoi, D. Loukopoulos, E. Terpos, Elisavet-Christine Vervessou, B. Schultheis, M. Emig, T. Ernst, E. Lengfelder, R. Hehlmann, A. Hochhaus, D. Oscier, R. Silver, A. Reiter, N. Cross (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.Blood, 106 6
-
A. Dunbar, L. Gondek, C. O'keefe, H. Makishima, Manjot Rataul, H. Szpurka, M. Sekeres, X. Wang, M. McDevitt, J. Maciejewski (2008)
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.Cancer research, 68 24
-
P. Fenaux, R. Beuscart, J. Laï, Jouet Jp, F. Bauters (1988)
Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 9
-
E. Feldman, J. Cortes, D. DeAngelo, T. Holyoake, B. Simonsson, S. O’Brien, J. Reiffers, A. Turner, G. Roboz, J. Lipton, F. Maloisel, P. Colombat, Giovanni Martinelli, J. Nielsen, S. Petersdorf, F. Guilhot, J. Barker, P. Kirschmeier, E. Frank, P. Statkevich, Yali Zhu, S. Loechner, A. List (2008)
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemiaLeukemia, 22
-
C. Ricci, E. Fermo, S. Corti, M. Molteni, A. Faricciotti, A. Cortelezzi, G. Deliliers, M. Beran, F. Onida (2010)
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative VariantClinical Cancer Research, 16
-
E Wattel, A Guerci, B Hecquet, T Economopoulos, A Copplestone, B Mahe (1996)
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemiaBlood, 88
-
C. Aul, N. Gattermann, A. Heyll, U. Germing, G. Derigs, W. Schneider (1992)
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.Leukemia, 6 1
-
D. Subirá, P. Font, L. Villalón, C. Serrano, E. Askari, E. Góngora, S. Castañón, R. Gonzalo, R. Mata, A. Román, P. Llamas (2008)
Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?Translational research : the journal of laboratory and clinical medicine, 151 5
-
S. Burgstaller, A. Reiter, N. Cross (2007)
BCR-ABL-negative chronic myeloid leukemiaCurrent Hematologic Malignancy Reports, 2
-
F. Grand, Claire Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. Mcguire, S. Kreil, A. Jones, J. Score, G. Metzgeroth, D. Oscier, A. Hall, C. Brandts, H. Serve, A. Reiter, A. Chase, N. Cross (2008)
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.Blood, 113 24
-
H. Eissa, Ted Gooley, M. Sorror, F. Nguyen, Bart Scott, K. Doney, Keith Loeb, P. Martin, J. Pagel, J. Radich, B. Sandmaier, E. Warren, R. Storb, F. Appelbaum, H. Deeg (2011)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 6
-
M. Kuo, D. Liang, C.-F. Huang, Y. Shih, J-h Wu, T. Lin, L. Shih (2009)
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformationLeukemia, 23
-
E. Wattel, A. Guerci, B. Hecquet, T. Economopoulos, A. Copplestone, B. Mahé, M. Couteaux, L. Resegotti, V. Voglová, C. Foussard, B. Pégourié, J. Michaux, E. Deconinck, A. Stoppa, G. Mufti, D. Oscier, P. Fenaux (1996)
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.Blood, 88 7
-
U. Germing, A. Kündgen, N. Gattermann (2004)
Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)Leukemia & Lymphoma, 45
-
M. Beran, S. Wen, Yu Shen, F. Onida, J. Jelinek, J. Cortes, F. Giles, H. Kantarjian (2007)
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring SystemLeukemia & Lymphoma, 48
-
J. Vardiman, J. Thiele, D. Arber, R. Brunning, M. Borowitz, A. Porwit, N. Harris, M. Beau, E. Hellström-Lindberg, A. Tefferi, C. Bloomfield (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.Blood, 114 5
-
U. Germing, N. Gattermann, H. Minning, A. Heyll, C. Aul (1998)
Problems in the classification of CMML--dysplastic versus proliferative type.Leukemia research, 22 10
-
W. Kern, U. Bacher, C. Haferlach, S. Schnittger, T. Haferlach (2011)
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cellsLeukemia & Lymphoma, 52
-
F. Onida, H. Kantarjian, T. Smith, G. Ball, M. Keating, E. Estey, A. Glassman, M. Albitar, M. Kwari, M. Beran (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.Blood, 99 3
-
R. Mcclure, G. Dewald, J. Hoyer, C. Hanson (1999)
Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical courseBritish Journal of Haematology, 106
-
S. Molica, Piergiorgio Iannaccaro, A. Alberti (1990)
Chronic myelomonocytic leukemia: A test of a proposed staging systemAmerican Journal of Hematology, 35
-
A. Orazi, R. Chiu, D. O’Malley, M. Czader, S. Allen, Caroline An, G. Vance (2006)
Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistologyModern Pathology, 19
-
E. Wong, J. Seymour, M. Kenealy, D. Westerman, Kirsten Herbert, M. Dickinson (2013)
Treatment of chronic myelomonocytic leukemia with azacitidineLeukemia & Lymphoma, 54
-
T. Siitonen, T. Timonen, E. Juvonen, Venla Terävä, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nyländen, E. Poikonen, A. Rauhala, M. Sinisalo, M. Suominen, E. Savolainen, P. Koistinen (2007)
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes.Haematologica, 92 8
-
O. Kosmider, V. Gelsi-Boyer, M. Ciudad, Cindy Racoeur, V. Jooste, N. Vey, B. Quesnel, P. Fenaux, J. Bastie, O. Beyne-Rauzy, A. Stamatoulas, F. Dreyfus, N. Ifrah, S. Botton, W. Vainchenker, O. Bernard, D. Birnbaum, M. Fontenay, E. Solary (2009)
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaHaematologica, 94
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer-Verlag Wien
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-012-0064-6
- Publisher site
- See Article on Publisher Site
Abstract
Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of the haematopoietic stem cell characterised by the presence of an absolute monocytosis in peripheral blood. The disease carries myelodysplastic and myeloproliferative features. This dilemma was sought to be overcome by the World Health Organization (WHO) in 2001, when CMML was classified within a new category of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). The identification of molecular markers in patients with CMML has dramatically increased over the past couple of years. However, the impact on prognosis and therapeutic interventions needs to be defined. Testing of new agents in the setting of CMML proves to be difficult due to limited number of patients. This review has a focus on current diagnosis including new molecular data and treatment of CMML.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jan 10, 2013